Nonclinical Development of SRK-181: An Anti-Latent TGFβ1 Monoclonal Antibody for the Treatment of Locally Advanced or Metastatic Solid Tumors

Checkpoint inhibitors offer a promising immunotherapy strategy for cancer treatment; however, due to primary or acquired resistance, many patients do not achieve lasting clinical responses. Recently, the transforming growth factor-β (TGFβ) signaling pathway has been identified as a potential target...

Descripción completa

Detalles Bibliográficos
Autores principales: Welsh, Brian T., Faucette, Ryan, Bilic, Sanela, Martin, Constance J., Schürpf, Thomas, Chen, David, Nicholls, Samantha, Lansita, Janice, Kalra, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135237/
https://www.ncbi.nlm.nih.gov/pubmed/33739172
http://dx.doi.org/10.1177/1091581821998945

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135237/
https://www.ncbi.nlm.nih.gov/pubmed/33739172
http://dx.doi.org/10.1177/1091581821998945

Ejemplares similares